Skip to main content
Premium Trial:

Request an Annual Quote

Informax Adds AxCell s Protein Interaction Module to Genomax Database

NEW YORK, Feb 20 – Using a database of human protein interactions produced by Cytogen subsidiary AxCell Biosciences, Informax has a new protein-protein interaction module for Genomax, its genomic and proteomic analysis bioinformatics platform, the companies announced Tuesday. 

"At the heart of many diseases are disruptions or alterations in protein-protein interaction networks," Alex Titomirov, InforMax CEO, said in a statement. "In order to better identify the complex interacting pathways involved in most cellular processes, scientists need to visualize these protein-protein interactions and correlate them with available sequence, expression, and functional information. The integration of our software with the AxCell database will allow subscribers to use this valuable information to obtain more complete answers to biologically relevant questions." 

The module includes a Graphical Affinity Matrix viewer that identifies the matrix of protein interactions; another viewer that shows the pathways by which proteins interact; tools that allow the user to sort data  to focus on specific relationships and save and cluster data. The module allows a user to view sequence information for molecules in a targeted pathway, and to have access to all molecules in Genomax’s database.

In January, AxCell announced that its scientists had mapped one of the body’s 60 to 80 protein domains, the WW domain. The company is now mapping the PDZ and SH3 domains, which have been associated with cancer, cardiovascular disease, stroke, and inflammatory ailments.

"We are very excited that AxCell's findings in mapping protein interactions, including the data from the WW Domain, will be available through Genomax,” said Brian Bullard, AxCell’s CIO. “This collaboration will bring the exciting research information in the IFP database to leaders in the pharmaceutical and biotechnology industries as we move closer to our goal of completing the map of all human protein interactions.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.